These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 18815480)

  • 1. Aspirin for the primary prevention of adverse cardiovascular events.
    Estes K; Thomure J
    Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin for primary prevention: do potential benefits outweigh the risks?
    Shakib S
    Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
    Adly G; Plakogiannis R
    Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical considerations in relation to aspirin prophylaxis.
    Morgan G
    Qual Prim Care; 2008; 16(6):433-40. PubMed ID: 19094419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis.
    Stalnikowicz-Darvasi R
    J Clin Gastroenterol; 1995 Jul; 21(1):13-6. PubMed ID: 7560825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin overprescription in primary cardiovascular prevention.
    Manes C; Giacci L; Sciartilli A; D'Alleva A; De Caterina R
    Thromb Res; 2006; 118(4):471-7. PubMed ID: 16321425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
    U.S. Preventive Services Task Force
    Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
    [No Abstract]   [Full Text] [Related]  

  • 9. [Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention].
    Volpe M; Abrignani MG; Borghi C; Coccheri S; Gresele P; Patti G; Trimarco B; De Caterina R
    G Ital Cardiol (Rome); 2014; 15(7-8):442-51. PubMed ID: 25174598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
    Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
    J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
    Mora S; Manson JE
    JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin in cardiology--benefits and risks.
    Björklund L; Wallander MA; Johansson S; Lesén E
    Int J Clin Pract; 2009 Mar; 63(3):468-77. PubMed ID: 19222632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
    Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
    Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
    Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
    Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin and gastrointestinal toxicity.
    Törüner M
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():27-30. PubMed ID: 18160364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
    Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
    Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events.
    Derogar M; Sandblom G; Lundell L; Orsini N; Bottai M; Lu Y; Sadr-Azodi O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):38-42. PubMed ID: 22975385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acetylsalicylic acid does not prevent cardiovascular disease. Poor scientific support for therapeutic guidelines according to primary prevention studies].
    Mooe T
    Lakartidningen; 2006 Sep 20-26; 103(38):2732-6. PubMed ID: 17058766
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.